Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) Could Burn Your Long Portfolio After More Shorts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment decreased to 1.17 in Q2 2019. Its down 0.32, from 1.49 in 2019Q1. It dived, as 36 investors sold Jazz Pharmaceuticals plc shares while 105 reduced holdings. 52 funds opened positions while 113 raised stakes. 50.63 million shares or 4.18% more from 48.59 million shares in 2019Q1 were reported.
Wedge L Limited Partnership Nc accumulated 255,460 shares or 0.42% of the stock. Hightower Advisors Llc stated it has 19,284 shares or 0.02% of all its holdings. Ameriprise has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Hillsdale Inc stated it has 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). First Republic Investment owns 4,579 shares. Alpine Woods Capital Limited Liability stated it has 0.68% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Hardman Johnston Global Advsrs Limited Liability holds 33,710 shares. Ranger Mngmt L P owns 33 shares for 0% of their portfolio. Ls Advsrs Limited Liability holds 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 773 shares. Mitsubishi Ufj Secs Limited invested in 0.01% or 30 shares. Jpmorgan Chase holds 2.25 million shares or 0.06% of its portfolio. Prelude Cap Management Lc owns 2,230 shares for 0.02% of their portfolio. Segall Bryant And Hamill Limited Liability invested in 2,295 shares or 0% of the stock. Moreover, Bb&T Ltd Limited Liability Company has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Engineers Gate Manager L P accumulated 6,562 shares.

The stock of Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) registered an increase of 10.97% in short interest. JAZZ’s total short interest was 2.24 million shares in October as published by FINRA. Its up 10.97% from 2.02 million shares, reported previously. With 499,000 shares average volume, it will take short sellers 5 days to cover their JAZZ’s short positions. The short interest to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 4.08%.

The stock increased 0.60% or $0.71 during the last trading session, reaching $118.67. About 369,908 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 19.23% since October 12, 2018 and is downtrending. It has underperformed by 19.23% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $6.72 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 10.76 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 4 analysts covering Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Jazz Pharmaceuticals plc – Ordinary Shares has $20800 highest and $14200 lowest target. $165.50’s average target is 39.46% above currents $118.67 stock price. Jazz Pharmaceuticals plc – Ordinary Shares had 5 analyst reports since May 8, 2019 according to SRatingsIntel. Piper Jaffray downgraded Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Wednesday, August 21. Piper Jaffray has “Neutral” rating and $14200 target. BMO Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Wednesday, May 8. BMO Capital Markets has “Outperform” rating and $20800 target. Mizuho maintained the stock with “Neutral” rating in Wednesday, May 8 report.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Finance.Yahoo.com which released: “TowerJazz Announces the Availability of its Newly Released Advanced Stacked BSI Hybrid Bonding Technology – Yahoo Finance” on September 25, 2019, also Seekingalpha.com with their article: “Why Investing In Jazz Pharmaceuticals Is A Game Of Musical Chairs – Seeking Alpha” published on September 18, 2019, Nasdaq.com published: “Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y – Nasdaq” on February 28, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Seekingalpha.com and their article: “Jazz Pharmaceuticals Q1 2019 Earnings Preview – Seeking Alpha” published on May 06, 2019 as well as Finance.Yahoo.com‘s news article titled: “Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex’s Osteoporosis Biosimilar – Yahoo Finance” with publication date: October 03, 2019.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.